Headache (HP:0002315)
Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve.
Synonyms: Headache, Headaches
Comment: Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition.
Pubmed References: PMID:15304572
Cross References: MSH:D006261, SNOMEDCT_US:25064002, UMLS:C0018681
KEGG Pathway
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | Pathways in cancer | 5.987e-14 | 7.664e-12 | 335.66 | 10219.54 |
| 2 | Gastric cancer | 3.165e-11 | 2.026e-9 | 208.19 | 5033.13 |
| 3 | Thyroid cancer | 6.931e-7 | 0.000006337 | 251.55 | 3567.44 |
| 4 | Central carbon metabolism in cancer | 2.843e-8 | 7.279e-7 | 201.25 | 3496.91 |
| 5 | Chronic myeloid leukemia | 3.973e-8 | 8.475e-7 | 184.43 | 3142.85 |
GO: Biological Process
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | negative regulation of gene silencing by miRNA (GO:0060965) | 0.00001481 | 0.001266 | 499.50 | 5554.53 |
| 2 | negative regulation of production of miRNAs involved in gene silencing by miRNA (GO:1903799) | 0.00001481 | 0.001266 | 499.50 | 5554.53 |
| 3 | positive regulation of histone H3-K4 methylation (GO:0051571) | 0.00002354 | 0.001266 | 384.17 | 4094.01 |
| 4 | response to muscle stretch (GO:0035994) | 0.00002354 | 0.001266 | 384.17 | 4094.01 |
| 5 | regulation of phospholipase C activity (GO:1900274) | 0.00002354 | 0.001266 | 384.17 | 4094.01 |
GO: Molecular Function
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | transcription coactivator binding (GO:0001223) | 1.021e-7 | 0.000003371 | 503.52 | 8105.11 |
| 2 | transcription coregulator binding (GO:0001221) | 9.117e-9 | 6.017e-7 | 271.31 | 5022.72 |
| 3 | I-SMAD binding (GO:0070411) | 0.00001750 | 0.0003850 | 454.07 | 4973.59 |
| 4 | RNA polymerase II general transcription initiation factor binding (GO:0001091) | 0.002498 | 0.01374 | 555.17 | 3326.77 |
| 5 | RNA-directed DNA polymerase activity (GO:0003964) | 0.002997 | 0.01413 | 444.11 | 2580.41 |
GO: Cellular Component
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | phosphatidylinositol 3-kinase complex, class I (GO:0097651) | 0.002498 | 0.03889 | 555.17 | 3326.77 |
| 2 | transferase complex, transferring phosphorus-containing groups (GO:0061695) | 0.004492 | 0.03889 | 277.53 | 1500.17 |
| 3 | Cul4A-RING E3 ubiquitin ligase complex (GO:0031464) | 0.005488 | 0.03889 | 222.00 | 1155.57 |
| 4 | beta-catenin-TCF complex (GO:1990907) | 0.006482 | 0.03889 | 184.98 | 932.06 |
| 5 | intercalated disc (GO:0014704) | 0.01540 | 0.04602 | 73.93 | 308.54 |
Hub genes predicted as biomarkers & predicted FDA approved drugs
| Hub Genes (ranked) | FDA-Approved Drugs |
| CTNNB1 | FLUORESCEN SODIUM |
| KRAS | PANITUMUMAB, CETUXIMAB |
| ESR1 | CLOMIPHENE, LEVONORGESTREL |
| KIT | NILOTINIB, IMATINIB |
| RET | CABOZANTINIB, VANDETANIB |
| SMAD4 | LYSINE, ALECTINIB |
| TERT | OMACETAXINE MEPESUCCINATE |
| PIK3CA | – |
| NF1 | TRAMETINIB, BINIMETINIB, COBIMETINIB, DABRAFENIB, VEMURAFENIB |
| CDKN1B | RALTITREXED |
